Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 21
1988 63
1989 102
1990 125
1991 164
1992 223
1993 268
1994 325
1995 329
1996 379
1997 393
1998 376
1999 424
2000 425
2001 468
2002 461
2003 496
2004 483
2005 495
2006 537
2007 561
2008 555
2009 473
2010 497
2011 513
2012 476
2013 483
2014 466
2015 400
2016 364
2017 345
2018 287
2019 292
2020 342
2021 337
2022 278
2023 234
2024 77

Text availability

Article attribute

Article type

Publication date

Search Results

12,406 results

Results by year

Filters applied: . Clear all
Page 1
PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target.
Altalhi R, Pechlivani N, Ajjan RA. Altalhi R, et al. Int J Mol Sci. 2021 Mar 20;22(6):3170. doi: 10.3390/ijms22063170. Int J Mol Sci. 2021. PMID: 33804680 Free PMC article. Review.
Hypofibrinolysis is a key abnormality in diabetes and contributes to the adverse vascular outcome in this population. Plasminogen activator inhibitor (PAI)-1 is an important regulator of the fibrinolytic process and levels of this antifibrinolytic protein are …
Hypofibrinolysis is a key abnormality in diabetes and contributes to the adverse vascular outcome in this population. Plasminogen activat …
Eupatilin Ameliorates Hepatic Fibrosis and Hepatic Stellate Cell Activation by Suppressing beta-catenin/PAI-1 Pathway.
Hu J, Liu Y, Pan Z, Huang X, Wang J, Cao W, Chen Z. Hu J, et al. Int J Mol Sci. 2023 Mar 21;24(6):5933. doi: 10.3390/ijms24065933. Int J Mol Sci. 2023. PMID: 36983006 Free PMC article.
Meanwhile, eupatilin markedly inhibited LX-2 cell proliferation, as verified by the reduced cell viability and down-regulation of c-Myc, cyclinB1, cyclinD1, and CDK6. Additionally, eupatilin decreased the level of PAI-1 in a dose-dependent manner, and knockdown of …
Meanwhile, eupatilin markedly inhibited LX-2 cell proliferation, as verified by the reduced cell viability and down-regulation of c-Myc, cyc …
Changes in uPA, PAI-1, and TGF-beta Production during Breast Cancer Cell Interaction with Human Mesenchymal Stroma/Stem-Like Cells (MSC).
Melzer C, von der Ohe J, Otterbein H, Ungefroren H, Hass R. Melzer C, et al. Int J Mol Sci. 2019 May 28;20(11):2630. doi: 10.3390/ijms20112630. Int J Mol Sci. 2019. PMID: 31142059 Free PMC article.
Moreover, uPA levels in 3D tumor spheroids remained elevated 9.4-fold above the average of five different human MSC cultures. In contrast, the expression of the corresponding plasminogen activator inhibitor type-1 (PAI-1) declined by 2.6-fold in the br …
Moreover, uPA levels in 3D tumor spheroids remained elevated 9.4-fold above the average of five different human MSC cultures. In cont …
Endothelial H(2)S-AMPK dysfunction upregulates the angiocrine factor PAI-1 and contributes to lung fibrosis.
Chen X, Wang H, Wu C, Li X, Huang X, Ren Y, Pu Q, Cao Z, Tang X, Ding BS. Chen X, et al. Redox Biol. 2024 Apr;70:103038. doi: 10.1016/j.redox.2024.103038. Epub 2024 Jan 11. Redox Biol. 2024. PMID: 38266576 Free PMC article.
One existing key gap is what sense the fibrotic risk to modulate the vascular angiocrine system in organ fibrosis. Here, using human and mouse data, we discovered that the metabolic pathway hydrogen sulfide (H(2)S)-AMP-activated protein kinase (AMPK) is a sensor of …
One existing key gap is what sense the fibrotic risk to modulate the vascular angiocrine system in organ fibrosis. Here, using human …
Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences.
Dewilde M, Van De Craen B, Compernolle G, Madsen JB, Strelkov S, Gils A, Declerck PJ. Dewilde M, et al. J Struct Biol. 2010 Jul;171(1):95-101. doi: 10.1016/j.jsb.2010.03.006. Epub 2010 Mar 15. J Struct Biol. 2010. PMID: 20230900
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) that plays an important role in cardiovascular disorders and tumor development. ...Sensitivity to PAI-1 inhibitory agents varied in different …
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) that plays an im …
PAI-1 in tissue fibrosis.
Ghosh AK, Vaughan DE. Ghosh AK, et al. J Cell Physiol. 2012 Feb;227(2):493-507. doi: 10.1002/jcp.22783. J Cell Physiol. 2012. PMID: 21465481 Free PMC article. Review.
The activities of uPA/tPA/plasmin and plasmin-dependent MMPs rely mostly on the activity of a potent inhibitor of uPA/tPA, plasminogen activator inhibitor-1 (PAI-1). Under normal physiologic conditions, PAI-1 c …
The activities of uPA/tPA/plasmin and plasmin-dependent MMPs rely mostly on the activity of a potent inhibitor of uPA/tPA, …
Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence.
Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK. Vaughan DE, et al. Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1446-1452. doi: 10.1161/ATVBAHA.117.309451. Epub 2017 Jun 1. Arterioscler Thromb Vasc Biol. 2017. PMID: 28572158 Free PMC article. Review.
PAI-1 (plasminogen activator inhibitor-1) is a member of the evolutionarily conserved serine protease inhibitor family and a potent and rapid-acting inhibitor of both of the mammalian plasminogen activators. Organismal homeostasis …
PAI-1 (plasminogen activator inhibitor-1) is a member of the evolutionarily conserved serine prote …
The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.
Van De Craen B, Declerck PJ, Gils A. Van De Craen B, et al. Thromb Res. 2012 Oct;130(4):576-85. doi: 10.1016/j.thromres.2012.06.023. Epub 2012 Jul 15. Thromb Res. 2012. PMID: 22801256 Review.
Plasminogen activator inhibitor-1 (PAI-1) is the primary physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) and is consequently one the most important inh …
Plasminogen activator inhibitor-1 (PAI-1) is the primary physiological inhibitor of both tissue-ty …
Plasminogen activator inhibitor-1 in cancer research.
Li S, Wei X, He J, Tian X, Yuan S, Sun L. Li S, et al. Biomed Pharmacother. 2018 Sep;105:83-94. doi: 10.1016/j.biopha.2018.05.119. Epub 2018 May 28. Biomed Pharmacother. 2018. PMID: 29852393 Review.
[Despite as a major inhibitor of urokinase (uPA), paradoxically,] Plasminogen activator inhibitor-1 (PAI-1) has been validated to be highly expressed in various types of tumor biopsy tissues or plasma compared with controls based on huge …
[Despite as a major inhibitor of urokinase (uPA), paradoxically,] Plasminogen activator inhibitor-1 (PAI- …
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.
Cesari M, Pahor M, Incalzi RA. Cesari M, et al. Cardiovasc Ther. 2010 Oct;28(5):e72-91. doi: 10.1111/j.1755-5922.2010.00171.x. Epub 2010 Jul 7. Cardiovasc Ther. 2010. PMID: 20626406 Free PMC article. Review.
METHODS: Narrative review. RESULTS: Plasminogen activator inhibitor-1 (PAI-1) is a member of the superfamily of serine-protease inhibitors (or serpins), and the principal inhibitor of both the tissue-type and the urokinase-type plasminoge …
METHODS: Narrative review. RESULTS: Plasminogen activator inhibitor-1 (PAI-1) is a member of the s …
12,406 results
You have reached the last available page of results. Please see the User Guide for more information.